| Literature DB >> 29942814 |
Munim Moiz1, Nick Smith1, Toby O Smith2, Amit Chawla1, Peter Thompson1, Andrew Metcalfe1,3.
Abstract
BACKGROUND: The first-line treatment for patellar dislocations is often nonoperative and consists of physical therapy and immobilization techniques, with various adjuncts employed. However, the outcomes of nonoperative therapy are poorly described, and there is a lack of quality evidence to define the optimal intervention.Entities:
Keywords: conservative; instability; knee injury; nonoperative; patella; patellofemoral
Year: 2018 PMID: 29942814 PMCID: PMC6009091 DOI: 10.1177/2325967118766275
Source DB: PubMed Journal: Orthop J Sports Med ISSN: 2325-9671
Figure 1.PRISMA flowchart. NTIS, National Technical Information Service.
Study Characteristics
| Author (Year) | Study Design | Type of Patellar Dislocation | No. of Patients | Age, y | Sex, Male/Female, n or % | Follow-up Period |
|---|---|---|---|---|---|---|
| Nikku et al[ | RCT | Primary | 55 | Mean, 19.1 | 25/30 | Mean, 25 mo (range, 20-45 mo) |
| Nikku et al[ | RCT | Primary | 57 | Mean, 20 | 70%/30% | Mean, 7 y (range, 6-9 y) |
| Christiansen et al[ | RCT | Primary | 35 | Mean, 19.9 (range, 13-39) | 18/17 | 2 y |
| Palmu et al[ | RCT | Primary | 27 | Mean ± SD, 13 ± 2 | 9/19 | Examined: 2 y; telephone interview: 6 y; final telephone interview: 14 y |
| Sillanpaa et al[ | RCT | Primary | 21 | Median, 20 (range, 19-21) | 20/2 (1 lost to follow-up) | Median, 7 y (range, 5-9 y) |
| Armstrong et al[ | RCT | Primary | 6 (immobilization: 3; no immobilization: 3) | Immobilization: median, 16 (range, 15-17); no immobilization: median, 28 (range, 16-38) | 2/1 | Immobilization: median, 12 wk (range, 1-20 wk); no immobilization: median, 8 wk (range, 5-12 wk); all followed up at 3 mo |
| Bitar et al[ | RCT | Primary | 18 | Mean ± SD, 24 ± 4.8 | 11/9 | Minimum, 2 y |
| Sillanpaa et al[ | RCT | Primary | 26 | Not provided | Not provided | Mean ± SD, 39 ± 8 mo |
| Rood et al[ | RCT | Primary | 18 (cast: 9; tape: 9) | Tape: mean, 26 (range, 18-44); cast: mean, 29 (range, 19-33) | 6/3 | 5 y (1 wk, 6 wk, 12 wk, 1 y, and 5 y) |
| Petri et al[ | RCT | Primary | 8 | Mean ± SD, 21.6 ± 5.6 | 62.5%/37.5% | 24 mo |
| Smith et al[ | RCT | Primary | 50 (VMS: 25; GQ: 25) | VMS: mean ± SD, 23.9 ± 7.5; GQ: mean ± SD, 23.0 ± 6.9 | 14/11 (1 lost to follow-up) | Baseline, 6 wk, 6 mo, and 12 mo |
| Ji et al[ | RCT | Primary | 56 (nonoperative: 26; operative: 30) | Not provided | 20/36 | Mean, 42 mo (range, 24-54 mo) |
| Arnbjornsson et al[ | Cohort | Recurrent | 21 | Mean, 39 (range, 26-69) | 7/22 | Mean, 14 y (range, 11-19 y); from initial injury: mean, 19 y (range, 13-25 y) |
| Buchner et al[ | Cohort | Primary | 83 (nonoperative: 63; operative: 20) | Mean, 21.1 (range, 10-52) | 35/28 | Nonoperative: mean, 8.2 y (range, 2-15 y); operative: mean, 8.4 y (range, 4-12 y) |
| Sillanpaa et al[ | Cohort | Primary | 35 | Median, 20 (range, 19-22) | 43/3 | Median, 7 y (range, 6-10 y) |
| Camanho et al[ | Non-RCT | Primary | 16 | Mean, 26.8 (range, 12-74) | 7/9 | Mean, 36.3 mo |
| Apostolovic et al[ | Non-RCT | Primary | 37 | Mean, 14.26 (range, 12-16) | 4/19 | Mean, 6.1 y (range, 5-8 y) |
| Moström et al[ | Cohort | Primary | 33 | Mean ± SD, 13.5 ± 1.3 | 17/16 | Mean ± SD, 7.7 ± 1.5 y (minimum, 5 y) |
| Sillanpaa et al[ | Cohort | Primary | 44 | Median, 23 (range, 15-31) | 44/12 (2 lost to follow-up) | Median, 4 y (range, 1-10 y) |
| Mäenpää et al[ | Case series | Primary | 100 | Recurrence: mean ± SD, 21 ± 9; nonrecurrence: mean ± SD, 27 ± 11 | Recurrence: 15/22; nonrecurrence: 13/25 | Median, 11 y (range, 6-24 y) |
| Mäenpää and Lehto[ | Case series | Primary | 100 | Plaster cast: mean ± SD, 23 ± 11; posterior splint: mean ± SD, 22 ± 9; bandage/brace: mean ± SD, 21 ± 9 | Plaster cast: 23/37; posterior splint: 8/9; bandage/brace: 6/17 | Mean, 13 y (range, 6-26 y) |
| Vengust et al[ | Case series | Recurrent | 11 | Not provided | Not provided | Not provided |
| Kang et al[ | Case series | Primary | 85 | Group 1: mean ± SD, 19.2 ± 6.1; group 2: mean ± SD, 20.1 ± 6.6 | 32/53 | At least 2 y; group 1: mean ± SD, 28.4 ± 5.1 mo; group 2: mean ± SD, 29.9 ± 8.4 mo |
| Magnussen et al[ | Case series | Primary | 104 | Mean ± SD, 23.8 ± 8.9 (range, 11-48) | 41/63 | Minimum, 2 y; mean, 3.4 y (range, 1.3-5.5 y) |
| Salonen et al[ | Case series | Primary | 20 | Mean, 25 (range, 19-45) | 7/13 | Mean, 8 y |
GQ, general quadriceps; RCT, randomized controlled trial; VMS, vastus medialis–specific.
Same patient population.
Data only for nonoperative study population.
Same patient population.
Some study information not provided in article (author could not be contacted).
Study Outcomes
| Author (Year) | Immobilization | Weightbearing | Quadriceps Exercises | PROM | PROM Score | Redislocation Rate (Follow-up), % | Operation Rate, % |
|---|---|---|---|---|---|---|---|
| Nikku et al[ | Yes (PSO) | Not specified | GQ | Lysholm and Hughston | Mean ± SD, 89.2 ± 10.7 and 90.1 ± 10.9, respectively | 30 (first at 11 mo) | |
| Nikku et al[ | Yes (PSO) | Full | GQ | Kujala and Hughston | Median, 90 (IQR, 82-97) and 94 (IQR, 84-96), respectively | 39 (7 y) | |
| Christiansen et al[ | Yes (KB) | Not specified | GQ | Kujala | Mean ± SD, 78.1 ± 15.9 | 20 (2 y) | |
| Palmu et al[ | Yes (PSO) | Full | GQ | Kujala | Mean ± SD, 88 ± 8 | 54 (6 y) and 71 (14 y) | 39 |
| Sillanpaa et al[ | Yes (PSO) | Full | GQ | Kujala | Median, 90 (range, 59-100) | 29 (median, 7 y) | 14 |
| Armstrong et al[ | Yes (KB) | Not specified | Not specified | Lysholm | Immobilization: median, 70 (range, 46-76); no immobilization: median, 88 (range, 68-91) | ||
| Bitar et al[ | Yes (KB) | Full | GQ | Kujala | Mean ± SD, 70.8 ± 19.2 | 35 (minimum, 2 y) | |
| Sillanpaa et al[ | Yes (KB) | Full | Not specified | Kujala | RROM: median, 93 (range, 73-100); FROM: median, 90 (range, 62-100) | FROM: 15.4; RROM: 7.7 (3 y) | |
| Rood et al[ | Yes (cast) | Full | GQ | Lysholm | Tape: median, 86 (1 y) and 100 (5 y); cast: median, 78 (1 y) and 76 (5 y) | Tape: 0; cast: 0 (5 y) | |
| Petri et al[ | Yes (KB) | Partial | Not specified | Kujala | 12 mo: mean ± SD, 79.9 ± 18.5; 24 mo: mean ± SD, 81.3 ± 19.2 | 37.5 (2 y) | |
| Smith et al[ | Yes (splint) | Not specified | VMS | NPI | VMS: median, 7.3 (range, 1.7-12.6); GQ: median, 3.2 (range, 0-10.8) | VMS: 12.5; GQ: 0 (1 y) | |
| Ji et al[ | Yes (KB) | Partial | GQ/VMS | Kujala | Nonoperative: mean ± SD, 80.19 ± 5.07; operative: mean ± SD, 93.57 ± 4.03 | Nonoperative: 11.5; operative: 3.3 (42 mo) | |
| Arnbjornsson et al[ | Not specified | Not specified | Not specified | Lysholm | Mean, 85 (range, 19-100) | 13.8 (14 y) | |
| Buchner et al[ | Yes (PSO) | Not specified | Not specified | Lysholm | Nonoperative: mean, 85.2; operative: mean, 85 | Nonoperative: 27; operative: 4 | Nonoperative: 13 |
| Sillanpaa et al[ | Yes (PSO) | Full | GQ | Kujala | Median, 89.5 (range, 59-100) | 23 (7 y) | 14 |
| Camanho et al[ | Yes (splint) | Not specified | VMS | Kujala | Mean, 69 | 57 | |
| Apostolovic et al[ | Yes (not specified) | Not specified | GQ | Cincinnati | Median, 332.14 (range, 210- 420) | 7.1 (1-3 y) | 20.2 |
| Moström et al[ | Yes (PSO) | Not specified | Not specified | Kujala | Mean ± SD, 84 ± 10 | 67 (7.7 y) | |
| Sillanpaa et al[ | Not specified | Not specified | GQ | Kujala | Median, 86 | 54.8 (4 y) | |
| Mäenpää et al[ | Yes (KB) | Not specified | GQ | Kujala | Recurrence: mean ± SD, 80 ± 14; nonrecurrence: mean ± SD, 83 ± 14 | 20 (2 y) and 45 (5 y) | Recurrence: 49; nonrecurrence: 19 |
| Mäenpää and Lehto[ | Yes (KB) | Not specified | GQ | Kujala | Plaster cast: mean ± SD, 80 ± 15; posterior splint: mean ± SD, 82 ± 11; bandage/brace: mean ± SD, 74 ± 18 | Plaster: 38 (9.2 at 2 y); posterior splint: 47 (7.5 at 2 y); bandage/brace: 57 (33 at 2 y) | |
| Vengust et al[ | Not specified | Not specified | GQ | Lysholm | Baseline: mean, 71; treatment: mean, 89.3 | ||
| Kang et al[ | Yes (KB) | Full | GQ/VMS | Kujala | Total: mean ± SD, 85.9 ± 14.1; group 1: mean ± SD, 91.1 ± 10.1; group 2: mean ± SD, 82.6 ± 15.3 | Total: 15.3 (2 y); group 1: 6.1; group 2: 21.2 | Total: 9.4; group 1: 6.1; group 2: 11.5 |
| Magnussen et al[ | Yes (KB) | Not specified | Not specified | KOOS | Mean ± SD, 78.9 ± 80.2 | 26.9 (3.4 y) | |
| Salonen et al[ | Not specified | Full | GQ | KOOS | Mean, 90 (range, 70-100) |
FROM, free range of movement; GQ, general quadriceps; IQR, interquartile range; KB, knee brace; KOOS, Knee injury and Osteoarthritis Outcome Score; NPI, Norwich Patellar Instability score; PROM, patient-reported outcome measure; PSO, patellar stabilizing orthosis; RROM, restricted range of movement; VMS, vastus medialis–specific.
Same patient population.
Same patient population.
Some study information not provided in article (author could not be contacted).
Data presented in the study for dislocations only for a subset of a total 16 nonoperative patients (14 patients with 1 predisposing factor).
Quality of Randomized Controlled Trials by Percentage Compliance With CONSORT Criteria
| Author (Year) | Percentage Compliance |
|---|---|
| Bitar et al[ | 61 |
| Christiansen et al[ | 78 |
| Ji et al[ | 54 |
| Nikku et al[ | 50 |
| Nikku et al[ | 73 |
| Palmu et al[ | 85 |
| Petri et al[ | 68 |
| Rood et al[ | 79 |
| Sillanpaa et al[ | 78 |
| Smith et al[ | 86 |
| Armstrong et al[ | 78 |
Quality of Cohort Studies by Star Rating on Newcastle-Ottawa Scale
| Author (Year) | Total Stars |
|---|---|
| Apostolovic et al[ | 7/9 |
| Arnbjornsson et al[ | 9/9 |
| Buchner et al[ | 7/9 |
| Camanho et al[ | 6/9 |
| Moström et al[ | 5/9 |
| Sillanpaa et al[ | 6/9 |
| Sillanpaa et al[ | 6/9 |
Quality of Case Series by Star Rating on Newcastle-Ottawa Scale
| Author (Year) | Total Stars |
|---|---|
| Kang et al[ | 6/6 |
| Mäenpää et al[ | 6/6 |
| Mäenpää et al[ | 6/6 |
| Magnussen et al[ | 5/6 |
| Salonen et al[ | 5/6 |
| Vengust et al[ | 4/6 |
Nonoperative Interventions
|
|
TROM, total range of motion; ROM, range of motion.